Agenda
Friday 9 December
| 12:00 - 14:00 | Registration and lunch | |
| 14:00 - 15:15 | Session 1: EMPA-KIDNEY - background, trial conduct and primary outcome |
|
| Welcome and introduction | Colin Baigent and Martin Landray |
|
| EMPA-KIDNEY design and baseline characteristics | Richard Haynes | |
| Primary outcome: overall and by components and subgroups | Will Herrington | |
| 15:15 - 15:45 | Break | |
| 15:45-17:00 | Session 2: EMPA-KIDNEY - other outcomes, safety analyses and meta-analysis |
|
| Secondary and tertiary outcomes; safety and laboratory analyses |
Richard Haynes | |
| Impact of diabetes on the effects of SGLT-2 inhibitors on kidney outcomes: a meta-analysis |
Kaitlin Mayne |
|
| 16:30 - 17:00 | Discussion |
|
| 18:10 | Coaches depart from reception for gala dinner |
Saturday 10 December
| 06:30 - 09:00 | Registration and breakfast | |
| 09:00 - 10:15 | Session 3: Diabetes, blood pressure and heart failure - what’s new from CTSU? |
|
| Relationship between blood pressure, kidney function and chronic kidney disease |
Natalie Staplin | |
| Does an aspirin a day keep heart failure away? | Michelle Goonasekera | |
| GLP-1 agonists and ASCEND-PLUS | Marion Mafham | |
| 10:15 - 10:45 | Break | |
| 10:45 - 12:00 | Session 4: Future work | |
| Post-trial follow-up plans and future work | Sarah Ng | |
| BI 690517 in patients with CKD: a phase 2 trial | Peter Rossing | |
| Study of Heart and Kidney Protection with BI 690517 | Parminder Judge | |
| 12:00 - 12:30 | Discussion | |
| 12:30 - 14:00 | Lunch and depart |